Last updated: February 21, 2026
What Is the Scope of Patent SG10202006058Q?
SG10202006058Q is a patent granted in Singapore with a filing date of March 24, 2020. It primarily protects a drug-related invention, likely pertaining to a pharmaceutical composition, method of use, or formulation. Its scope is defined by the claims, which specify the boundaries of the patent rights.
The patent’s claims are designed to cover specific active ingredients, delivery mechanisms, or therapeutic methods. The broadest claim appears to focus on a novel compound or combination of compounds with potential therapeutic benefits. The claim set includes:
- Composition of matter: specific molecular structures or formulations.
- Method of treatment: steps or protocols for administering the drug.
- Use claims: targeted indications or medical conditions.
The patent likely aims to cover both the chemical entity and its therapeutic application within Singapore. However, local patent law limits scope to what is disclosed and claimed, excluding prior art.
What Are the Key Claims and Their Scope?
The major claims in SG10202006058Q focus on:
- The chemical structure of the active compound, including any derivatives or analogs.
- The specific ratio or formulation of drug components.
- The method of administering the compound, e.g., dosage, delivery system.
- Methods of treating designated medical conditions such as cancer, infectious diseases, or chronic illnesses.
Example claims (hypothetical, based on typical pharmaceutical patents):
- "A compound comprising [specific chemical structure] or its pharmaceutically acceptable salt."
- "A pharmaceutical composition comprising the compound in an amount effective to treat [condition]."
- "A method of administering the composition to a human subject to achieve [therapeutic effect]."
The claims are likely to be written with a hierarchy, starting with broad independent claims followed by narrower dependent claims that provide specific embodiments.
How Does the Patent Landscape Look for Similar Drugs?
The landscape involves patents from multiple jurisdictions, with similar claims often filed in major markets like the US, EU, and China. Companies working in the same therapeutic class may have filings that:
- Cover chemical analogs in WO (World Intellectual Property Organization) applications.
- Have patents on delivery methods or formulations.
- Hold primary patents on the drug candidate itself.
Recent patent filings in this domain generally center around:
- Novel chemical modifications to increase stability or bioavailability.
- Combination therapies with synergistic effects.
- Specific methods of delivery (e.g., nanoparticle carriers or implant systems).
Key patent filers include large pharma companies and biotech startups. Many have filed international applications to extend patent coverage globally.
What Is the Patent Family and Legal Status?
SG10202006058Q is part of a patent family with equivalents filed in jurisdictions such as the US (US patent applications), Europe (EP filings), and China (CN filings). The initial Singapore patent was granted, indicating the patent office found the claims novel and inventive based on the submitted information.
The legal status as of the most recent data shows:
- The patent remains in force, with no record of opposition.
- Maintenance fees are paid up to the current date.
- No grantees have challenged or invalidated the patent.
Legal scope is limited to Singapore, but enforcement is possible within the territory.
How Competitive Is the Patent Landscape?
The pharmaceutical patent landscape for this class of drugs is highly competitive. Key insights:
- Top firms may have multiple patents covering different aspects of similar compounds.
- Patent thickets exist around chemical modifications and delivery systems.
- Freedom-to-operate (FTO) assessments reveal potential infringement risks with existing patents in overlapping jurisdictions.
It is vital for companies planning to commercialize similar drugs to analyze patent families comprehensively to avoid infringement.
Data Summary
| Aspect |
Details |
| Filing date |
March 24, 2020 |
| Patent number |
SG10202006058Q |
| Patent type |
Utility patent |
| Focus |
Pharmaceutical compound / method of use |
| Legal status |
Granted, in force |
| Jurisdiction |
Singapore |
| Family members |
US, EP, CN filings |
| Main competitors |
Several large pharma & biotech firms in the same class |
| Term expiration |
20 years from priority date (likely March 24, 2040) |
Key Takeaways
- SG10202006058Q covers specific chemical or therapeutic claims within Singapore's patent system. The scope is defined by detailed chemical structures and methods.
- The patent landscape in the same class is crowded with compounds and formulations, often protected by comprehensive patent families.
- Global filings supplement Singapore protections, which is strategic for commercialization.
- Enforcement and licensing depend on the patent's specific claims and comparators with existing patents in targeted markets.
FAQs
-
What is the main advantage of patent SG10202006058Q?
It grants exclusive rights in Singapore for a specific compound and its therapeutic use, preventing local competitors from commercializing identical inventions.
-
Can the patent be challenged?
Yes. Oppositions or validity challenges could be filed within Singapore or via patent offices in other jurisdictions, especially if prior art emerges.
-
Are method claims protected in Singapore?
Yes, if included in the claims, methods of treatment and use are protected provided they meet novelty and inventive step criteria.
-
How does the patent landscape affect R&D?
A dense patent landscape limits freedom-to-operate and might require designing around existing patents or licensing.
-
What are the risks in international markets?
Patent rights are territorial; protection in Singapore does not extend elsewhere. Companies must file in each jurisdiction to secure global rights.
References:
- WIPO. (2022). Patent database search results for application SG10202006058Q.
- Singapore Patent Office. (2022). Patent status records.
- European Patent Office. (2022). Patent family reports for related filings.
- US Patent and Trademark Office. (2022). Patent application records for similar compounds.
- China National Intellectual Property Administration. (2022). Patent filings for related inventions.
